__NUXT_JSONP__("/drugs/Rilotumumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"872514-65-3",chebiId:b,chemicalFormula:b,definition:"A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.",fdaUniiCode:"51WEW898IJ",identifier:"C67079",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["AMG 102","Anti-HGF Monoclonal Antibody AMG 102","Fully Human Anti-HGF Monoclonal Antibody AMG 102","RILOTUMUMAB",a,"anti-HGF monoclonal antibody AMG 102"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRilotumumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Rilotumumab","","2021-10-30T13:43:12.193Z")));